X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-11-13 | EXAS | Conroy Kevin T | Pres, CEO | P - Purchase | $51.35 | +19,500 | 1,414,311 | +1% | +$1,001,325 | ||||||
2024-10-08 | EXAS | Baranick Brian | EVP, GM, Precision Oncology | S - Sale | $70.00 | -929 | 13,212 | -7% | -$65,030 | ||||||
2024-09-18 | EXAS | Baranick Brian | EVP, GM, Precision Oncology | S - Sale | $70.00 | -929 | 14,141 | -6% | -$65,030 | ||||||
2024-05-01 | EXAS | Coward D Scott | Dir | S - Sale | $60.15 | -67 | 49,337 | 0% | -$4,030 | ||||||
2024-05-01 | EXAS | Cunningham Everett | Chief Commercial Officer | S - Sale | $60.15 | -136 | 47,613 | 0% | -$8,180 | ||||||
2024-05-01 | EXAS | Herriott James | SVP, GC, Sec | S - Sale | $60.15 | -30 | 11,049 | 0% | -$1,805 | ||||||
2024-05-01 | EXAS | Elliott Jeffrey Thomas | CFO | S - Sale | $60.15 | -136 | 13,380 | -1% | -$8,180 | ||||||
2024-05-01 | EXAS | Baranick Brian | EVP, GM., Precision Oncology | S - Sale | $60.15 | -110 | 13,733 | -1% | -$6,617 | ||||||
2024-05-01 | EXAS | Condella Sarah | EVP, HR | S - Sale | $60.15 | -102 | 78,337 | 0% | -$6,135 | ||||||
2024-05-01 | EXAS | Orville Jacob A | GM, Screening | S - Sale | $60.15 | -102 | 15,557 | -1% | -$6,135 | ||||||
2024-05-01 | EXAS | Conroy Kevin T | Pres, CEO | S - Sale | $60.15 | -1,155 | 1,394,770 | 0% | -$69,473 | ||||||
2024-04-01 | EXAS | Condella Sarah | EVP, HR | S - Sale | $70.00 | -2,000 | 77,513 | -3% | -$140,000 | ||||||
2024-04-02 | EXAS | Baranick Brian | EVP, GM., Precision Oncology | S - Sale | $79.43 | -924 | 13,625 | -6% | -$73,393 | ||||||
2024-03-28 | EXAS | Condella Sarah | EVP, HR | S - Sale | $70.00 | -2,000 | 79,513 | -2% | -$140,000 | ||||||
| D | 2024-03-01 | EXAS | Orville Jacob A | GM, Screening | S - Sale+OE | $59.32 | -2,154 | 15,441 | -12% | -$127,775 | |||||
2024-03-01 | EXAS | Levangie Daniel J | Dir | S - Sale | $57.50 | -5,000 | 22,975 | -18% | -$287,500 | ||||||
| D | 2024-03-01 | EXAS | Herriott James | GC | S - Sale+OE | $59.32 | -862 | 10,308 | -8% | -$51,134 | |||||
| D | 2024-03-01 | EXAS | Elliott Jeffrey Thomas | CFO | S - Sale+OE | $59.32 | -2,412 | 12,518 | -16% | -$143,080 | |||||
2024-03-01 | EXAS | Doyle James Edward | Dir | S - Sale | $57.50 | -2,000 | 50,110 | -4% | -$115,000 | ||||||
| D | 2024-03-01 | EXAS | Cunningham Everett | Chief Commercial Officer | S - Sale+OE | $59.32 | -2,412 | 46,750 | -5% | -$143,080 | |||||
| D | 2024-03-01 | EXAS | Conroy Kevin T | Pres, CEO | S - Sale+OE | $59.32 | -8,271 | 1,392,609 | -1% | -$490,636 | |||||
| D | 2024-03-01 | EXAS | Condella Sarah | EVP, HR | S - Sale+OE | $59.32 | -1,724 | 81,513 | -2% | -$102,268 | |||||
| D | 2024-03-01 | EXAS | Baranick Brian | Gen. Mgr., Precision Oncology | S - Sale+OE | $59.32 | -2,323 | 14,549 | -14% | -$137,800 | |||||
| D | 2024-02-27 | EXAS | Orville Jacob A | GM, Screening | S - Sale+OE | $56.89 | -1,879 | 12,871 | -13% | -$106,896 | |||||
| D | 2024-02-27 | EXAS | Herriott James | GC | S - Sale+OE | $56.89 | -784 | 9,280 | -8% | -$44,602 | |||||
| D | 2024-02-27 | EXAS | Cunningham Everett | Chief Commercial Officer | S - Sale+OE | $56.89 | -3,648 | 43,871 | -8% | -$207,535 | |||||
| D | 2024-02-27 | EXAS | Elliott Jeffrey Thomas | CFO | S - Sale+OE | $56.89 | -2,710 | 9,639 | -22% | -$154,172 | |||||
| D | 2024-02-27 | EXAS | Conroy Kevin T | Pres, CEO | S - Sale+OE | $56.89 | -6,263 | 1,382,737 | 0% | -$356,302 | |||||
| D | 2024-02-27 | EXAS | Condella Sarah | EVP, HR | S - Sale+OE | $56.89 | -1,880 | 79,458 | -2% | -$106,953 | |||||
| D | 2024-02-27 | EXAS | Baranick Brian | Gen. Mgr., Precision Oncology | S - Sale+OE | $56.89 | -2,027 | 12,148 | -14% | -$115,316 | |||||
2024-02-23 | EXAS | Condella Sarah | EVP, HR | S - Sale | $59.72 | -1,021 | 77,384 | -1% | -$60,974 | ||||||
2024-02-22 | EXAS | Orville Jacob A | GM, Screening | S - Sale | $59.78 | -1,013 | 10,796 | -9% | -$60,557 | ||||||
2024-02-22 | EXAS | Herriott James | GC | S - Sale | $59.78 | -291 | 8,416 | -3% | -$17,396 | ||||||
2024-02-22 | EXAS | Elliott Jeffrey Thomas | CFO | S - Sale | $59.78 | -1,351 | 6,648 | -17% | -$80,763 | ||||||
2024-02-22 | EXAS | Cunningham Everett | Chief Commercial Officer | S - Sale | $59.78 | -1,350 | 39,841 | -3% | -$80,703 | ||||||
2024-02-22 | EXAS | Coward D Scott | Dir | S - Sale | $59.78 | -663 | 49,187 | -1% | -$39,634 | ||||||
2024-02-22 | EXAS | Conroy Kevin T | Pres, CEO | S - Sale | $59.78 | -11,565 | 1,334,542 | -1% | -$691,356 | ||||||
2024-02-22 | EXAS | Condella Sarah | EVP, HR | S - Sale | $59.78 | -1,013 | 78,405 | -1% | -$60,557 | ||||||
2024-02-22 | EXAS | Baranick Brian | Gen. Mgr., Precision Oncology | S - Sale | $59.78 | -1,093 | 10,221 | -10% | -$65,340 | ||||||
| D | 2024-02-21 | EXAS | Orville Jacob A | GM, Screening | S - Sale+OE | $61.50 | -1,078 | 9,775 | -10% | -$66,297 | |||||
| D | 2024-02-21 | EXAS | Herriott James | GC | S - Sale+OE | $61.50 | -415 | 8,126 | -5% | -$25,523 | |||||
| D | 2024-02-21 | EXAS | Elliott Jeffrey Thomas | CFO | S - Sale+OE | $61.50 | -1,493 | 5,288 | -22% | -$91,820 | |||||
| D | 2024-02-21 | EXAS | Coward D Scott | Dir | S - Sale+OE | $61.50 | -706 | 47,816 | -1% | -$43,419 | |||||
| D | 2024-02-21 | EXAS | Conroy Kevin T | Pres, CEO | S - Sale+OE | $61.50 | -4,975 | 1,322,869 | 0% | -$305,963 | |||||
| D | 2024-02-21 | EXAS | Condella Sarah | EVP, HR | S - Sale+OE | $61.50 | -1,079 | 77,384 | -1% | -$66,359 | |||||
| D | 2024-02-21 | EXAS | Baranick Brian | Gen. Mgr., Precision Oncology | S - Sale+OE | $61.50 | -895 | 9,280 | -9% | -$55,043 | |||||
| D | 2024-02-15 | EXAS | Orville Jacob A | GM, Screening | S - Sale+OE | $61.43 | -966 | 8,303 | -10% | -$59,341 | |||||
| D | 2024-02-15 | EXAS | Herriott James | GC | S - Sale+OE | $61.43 | -421 | 7,375 | -5% | -$25,862 | |||||
| D | 2024-02-15 | EXAS | Elliott Jeffrey Thomas | CFO | S - Sale+OE | $61.43 | -1,888 | 3,397 | -36% | -$115,980 | |||||
| D | 2024-02-15 | EXAS | Coward D Scott | Dir | S - Sale+OE | $61.43 | -1,376 | 46,274 | -3% | -$84,528 | |||||
| D | 2024-02-15 | EXAS | Conroy Kevin T | Pres, CEO | S - Sale+OE | $61.43 | -14,791 | 1,317,146 | -1% | -$908,611 | |||||
| D | 2024-02-15 | EXAS | Condella Sarah | EVP, HR | S - Sale+OE | $61.43 | -965 | 75,914 | -1% | -$59,280 | |||||
2024-01-02 | EXAS | Condella Sarah | EVP, HR | S - Sale | $73.50 | -2,000 | 74,848 | -3% | -$147,000 | ||||||
2024-01-02 | EXAS | Baranick Brian | Gen. Mgr., Precision Oncology | S - Sale | $73.50 | -879 | 8,290 | -10% | -$64,607 | ||||||
2023-12-14 | EXAS | Condella Sarah | EVP, HR | S - Sale | $70.00 | -2,000 | 76,848 | -3% | -$140,000 | ||||||
| D | 2023-10-12 | EXAS | Cunningham Everett | Chief Commercial Officer | S - Sale+OE | $66.49 | -13,007 | 38,178 | -25% | -$864,835 | |||||
2023-09-01 | EXAS | Condella Sarah | EVP, HR | S - Sale | $84.36 | -4,500 | 78,848 | -5% | -$379,620 | ||||||
2023-08-21 | EXAS | Elliott Jeffrey Thomas | CFO | S - Sale | $82.92 | -30,210 | 1,313 | -96% | -$2,505,013 | ||||||
| D | 2023-08-07 | EXAS | Baranick Brian | Gen. Mgr., Precision Oncology | S - Sale+OE | $85.04 | -1,350 | 9,169 | -13% | -$114,804 | |||||
2023-07-27 | EXAS | Doyle James Edward | Dir | S - Sale | $97.42 | -2,000 | 52,110 | -4% | -$194,840 | ||||||
2023-07-19 | EXAS | Herriott James | GC | S - Sale | $100.00 | -1,300 | 6,845 | -16% | -$130,000 | ||||||
2023-06-09 | EXAS | Doyle James Edward | Dir | S - Sale | $90.51 | -1,402 | 54,110 | -3% | -$126,895 | ||||||
2023-06-09 | EXAS | Zanotti Katherine S | Dir | S - Sale | $90.51 | -3,027 | 64,629 | -4% | -$273,974 | ||||||
2023-06-08 | EXAS | Herriott James | GC | S - Sale | $90.00 | -1,300 | 8,145 | -14% | -$117,000 | ||||||
2023-05-26 | EXAS | Doyle James Edward | Dir | S - Sale | $80.62 | -2,000 | 51,913 | -4% | -$161,240 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |